Agonist/antagonist treatment . | nmol carbonyl mg–1 protein . |
---|---|
Control | 7.936±1.12 |
2 μmol l–1 Cariporide | 7.737±1.5 |
2 μmol l–1 Cytochalasin D | 7.717±1.3 |
0.01 mmol l–1 Forskolin | 7.799±1.4 |
50 nmol l–1 Wortmannin | 8.128±0.9 |
11 μmol l–1 GF-109203X | 7.689±1.2 |
10 μmol l–1 L-NAME | 10.059±1.3 |
10 μmol l–1 DPI | 7.991±1.5 |
Agonist/antagonist treatment . | nmol carbonyl mg–1 protein . |
---|---|
Control | 7.936±1.12 |
2 μmol l–1 Cariporide | 7.737±1.5 |
2 μmol l–1 Cytochalasin D | 7.717±1.3 |
0.01 mmol l–1 Forskolin | 7.799±1.4 |
50 nmol l–1 Wortmannin | 8.128±0.9 |
11 μmol l–1 GF-109203X | 7.689±1.2 |
10 μmol l–1 L-NAME | 10.059±1.3 |
10 μmol l–1 DPI | 7.991±1.5 |
Cells were exposed to each agonist or antagonist alone, without the addition of cadmium
Values are means ± s.d. of triplicate samples from three independent experiments
No significant difference was obtained between control cells and cells treated with each agonist and antagonist as determined by Dunnet test, P<0.01